[144] Crinetics Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) reports a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $154,950.00. The shares were acquired and will be paid for by exercise of stock options on 09/02/2025 and sale is expected the same date on NASDAQ. The filing also discloses recent 10b5-1 sales by Dana Pizzuti totaling 36,492 shares for gross proceeds of $1,102,425.82 executed on 08/20/2025 and 08/22/2025. The filer affirms no undisclosed material adverse information.

Positive

• Compliance with Rule 144 disclosure: The filing provides acquisition date, nature of acquisition, broker, sale date, and market value.
• Use of 10b5-1 plan for prior sales: Prior disposals on 08/20/2025 and 08/22/2025 were executed under 10b5-1, indicating preplanned trades.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale following option exercise; modest size relative to outstanding shares, unlikely to be market-moving.

The notice documents an insider exercising options and proposing to sell 5,000 shares valued at $154,950, representing approximately 0.0053% of the 94,175,994 shares outstanding reported in the form. Prior 10b5-1 sales by the same person totaled 36,492 shares for $1,102,425.82, indicating planned, prearranged disposition activity rather than ad hoc large disposals. For investors, the transactions are material as insider activity but small in absolute and relative terms.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 and 10b5-1 protocols; signatures and representations included.

The filing includes required representations that the seller does not possess undisclosed material information and references a 10b5-1 trading arrangement for prior sales. The transaction was routed through Morgan Stanley Smith Barney LLC. Documentation shows timing of acquisition and payment on 09/02/2025 via option exercise, satisfying Rule 144 disclosure elements. No governance or compliance concerns are evident from the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5000	154950.00	94175994	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Exercise of Stock Options	Issuer			5000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	08/22/2025	30000	912999.00
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	08/20/2025	6492	189426.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the Form 144 for CRNX report?

5,000 common shares of Crinetics Pharmaceuticals proposed for sale on NASDAQ.

How were the 5,000 CRNX shares acquired?

Exercise of stock options on 09/02/2025 with payment in cash on the same date.

Who is the broker handling the proposed sale of CRNX shares?

Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY).

What recent insider sales by the same person are disclosed?

10b5-1 sales on 08/20/2025 (6,492 shares, $189,426.82) and 08/22/2025 (30,000 shares, $912,999.00).

How large is the proposed sale relative to outstanding shares?

The proposed 5,000 shares represent approximately 0.0053% of the reported 94,175,994 shares outstanding in the form.